Results 101 to 110 of about 1,229 (138)
Some of the next articles are maybe not open access.
The British Journal of Radiology, 1987
The misonidazole (MISO) “pre-incubation” effect, whereby the sensitiser-enhancement ratio (SER) is increased following prolonged exposure of cells in hypoxia to MISO, was first demonstrated by Hall and Biaglow (1977). Subsequently, Wong et al (1978) showed that hypoxic cells incubated with 0.5 mM MISO for several hours at 37°C had an increased ...
N J, McNally +3 more
openaire +2 more sources
The misonidazole (MISO) “pre-incubation” effect, whereby the sensitiser-enhancement ratio (SER) is increased following prolonged exposure of cells in hypoxia to MISO, was first demonstrated by Hall and Biaglow (1977). Subsequently, Wong et al (1978) showed that hypoxic cells incubated with 0.5 mM MISO for several hours at 37°C had an increased ...
N J, McNally +3 more
openaire +2 more sources
Modification of the Action of Misonidazole Effect of TAN on Radiosensitization
International Journal of Radiation Biology and Related Studies in Physics, Chemistry and Medicine, 1980Radiosensitization by misonidazole of hypoxic mammalian cells in dilute suspension is modified by the presence of the stable free radical, TAN. The dose modifying factor (DMF) of 15mM misonidazole is 2x4 for cell inactivation, and 3x5 for the production of single-strand breaks in DNA.
K A, Skov +3 more
openaire +2 more sources
Cellular and chemical reduction products of misonidazole
Chemico-Biological Interactions, 1981Misonidazole is readily reduced by zinc dust in aqueous solution in the presence of ammonium chloride. High pressure liquid chromatographic (HPLC) separation of the reduction mixture revealed the presence of three products. These were identified as the hydroxylamine, amine and the hydrazo derivative of misonidazole.
A J, Varghese, G F, Whitmore
openaire +2 more sources
Somatosensory deficits in monkeys treated with misonidazole
Toxicology and Applied Pharmacology, 1981Misonidazole, a hypoxic cell radiosensitizer, can produce peripheral sensory disorders in humans. It has been studied in monkeys with a computer-controlled system for evaluating vibration sensitivity. Monkeys were trained to report when vibration was stimulating the finger tip. Sinusoidal vibrations of several frequencies were presented.
J P, Maurissen +5 more
openaire +2 more sources
Misonidazole—A drug for trial in radiotherapy and oncology
International Journal of Radiation Oncology*Biology*Physics, 1979Abstract Misonidazole is an hypoxic cell radiosensitizer with promise in clinical radiotherapy. The concentrations which may be achieved in plasma, in tumors and in normal tissues are discussed. The toxic effects of misonidazole are described and schemes for the safe administration in man detailed.
S, Dische +4 more
openaire +2 more sources
Biochemical Pharmacology, 1980
Abstract Misonidazole [1-(2-nitroimidazol-1-yl)-3-methoxypropan-2-ol; Ro 07-0582] selectively sensitizes hypoxic cells to radiation and is undergoing clinical trial in the radiation treatment of solid tumours. It has been suggested that the glucocorticoid hormone dexamethasone may reduce the incidence of neurotoxicity, the dose-limiting side effect ...
openaire +2 more sources
Abstract Misonidazole [1-(2-nitroimidazol-1-yl)-3-methoxypropan-2-ol; Ro 07-0582] selectively sensitizes hypoxic cells to radiation and is undergoing clinical trial in the radiation treatment of solid tumours. It has been suggested that the glucocorticoid hormone dexamethasone may reduce the incidence of neurotoxicity, the dose-limiting side effect ...
openaire +2 more sources
Clinical studies with misonidazole.
The British journal of cancer. Supplement, 1978The preliminary details of a randomized clinical trial of misonidazole for the radiotherapy of Grades 3 and 4 cerebral astrocytoma are described. Plasma concentrations of misonidazole and its O-demethylated metabolite, determined by high-pressure liquid chromatography analysis, are reported for 8 patients with astrocytoma, 1 with carcinoma of the ...
C R, Wiltshire +3 more
openaire +1 more source
Reductive metabolism and DNA binding of misonidazole
Toxicology and Applied Pharmacology, 1989Misonidazole (1-(2-nitro-1-imidazolyl)-3-methoxy-2-propanol) is an experimental anticancer drug. Reductive metabolism is thought to be important for the cytotoxicity of misonidazole. In this study, the DNA binding of misonidazole was examined after chemical and enzymatic reduction.
openaire +2 more sources
Plasma concentrations of misonidazole.
Strahlentherapie, 1981The plasma concentrations of misonidazole doses between 0.6 and 2.0 g/m2 were analyzed in respect to the variation within the same patient and between different patients. Peak plasma levels were observed after 2 hours. The mean plasma levels of misonidazole only at 3 hours were 23.8, 47.0 and 76.5 microgram/ml after misonidazole doses of 0.6, 1.2 and 2.
G, Notter, U, Rylander, I, Turesson
openaire +1 more source